The Great Repricing: Expanding Government Reach of Pricing Control

In parts 1 and 2 of “The Great Repricing” series, we explored the fragmentation of the U.S. pharmaceutical market into three payer economies — commercial, government and self-pay — and examined the growing structural pressure on the commercial channel and pharmacy benefit manager model. In this installment, we turn to the most consequential of the three: government.

Government is no longer a secondary payer reacting to or following commercial market dynamics. The Department of Health and Human Services and the Centers for Medicare & Medicaid Services have increasingly become the price setters, establishing reimbursement ceilings, compliance frameworks and pricing rules that reverberate across the entire pharmaceutical ecosystem.

This shift is not ideological. It is mathematical. Government is the dog and no longer the tail.

Government Is No Longer a Segment of the Market

For decades, government programs were treated as a defined but manageable portion of the pharmaceutical market. Manufacturers focused primarily on commercial coverage while managing government exposure as a compliance obligation.

That framing no longer reflects reality.

When Medicare, Medicaid, 340B-covered entities, the Veterans Health Administration, the Department of Defense, TRICARE and the Indian Health Service are combined, government-linked programs now influence well over half of U.S. prescription utilization and an even larger share of net price exposure.

More importantly, government pricing mechanisms increasingly dictate the boundaries within which commercial strategies must operate. Commercial pricing decisions cascade into government liability through mechanisms such as:

• Medicaid Best Price
• Medicaid inflationary rebate penalties
• 340B ceiling price calculations
• Federal Supply Schedule (FSS) pricing
• Medicare Part B inflation rebates
• Medicare Part D negotiated pricing

In today’s environment, government pricing is no longer downstream of commercial strategy; it is upstream and increasingly determinative.

The Inflation Reduction Act Reset the Pricing Framework

The Inflation Reduction Act (IRA) fundamentally altered the pricing architecture of the U.S. pharmaceutical market.

Although public debate centered on Medicare’s authority to negotiate prices, the broader structural impact is even more significant. The introduction of the maximum fair price (MFP) mechanism effectively creates a government-enforced reference price outside traditional rebate negotiations.

Equally consequential are the inflation rebate provisions for Medicare Parts B and D. These provisions penalize manufacturers for price increases above the Consumer Price Index for All Urban Consumers (CPI-U), transforming list price growth from a revenue lever into a liability.

For decades, list price increases functioned as the economic engine supporting commercial rebates and formulary access. Under the IRA framework, that strategy now carries asymmetric downside risk.

In effect, list price has transitioned from a strategic asset to a compliance exposure.

Medicaid: The Program That Changes the Math

No government program better illustrates the new repricing reality than Medicaid.

Historically, the Medicaid Drug Rebate Program included a cap limiting total rebate liability to 100 percent of the drug’s average manufacturer price. The removal of that cap dramatically altered manufacturer risk exposure.

Today, Medicaid rebates can exceed a product’s list price, particularly for older brands with long histories of price increases. When best price obligations, inflation penalties and managed Medicaid supplemental rebates are layered together, manufacturers can find themselves paying states more than they receive in revenue.

Medicaid is therefore no longer simply a low-margin payer. In certain cases, it can become a negative-margin payer.

This reality forces manufacturers to confront a question that would have been almost unthinkable a decade ago: Does incremental Medicaid volume create enterprise value, or destroy it?

As manufacturers evaluate pricing strategies for the self-pay and cash markets, it can be helpful to think of Medicaid as a bundled pricing model. Older products that conceded aggressive discounting combined with wholesale acquisition cost (WAC) price increases above CPI during that period may now be operating at a loss, while newer therapies may reflect a more balanced value exchange.

In some cases, self-pay and cash pricing may be set below the Medicaid Best Price, 340B ceiling price or FSS price. We will explore this dynamic further in the next article in the series.

340B: From Safety Net to Market Force

As the industry well knows, the 340B Drug Pricing Program was originally designed as a targeted safety-net initiative to support hospitals and clinics serving economically vulnerable populations. Over time, however, the program has expanded dramatically in both scope and influence, often functioning as a margin-enhancing mechanism for hospitals and pharmacies.

The proliferation of contract pharmacy networks has extended the program far beyond the point of care, introducing additional layers of margin capture and administrative complexity. As a result, manufacturers have experienced significant net price erosion across many therapeutic categories.

Participation in the 340B program is effectively mandatory for manufacturers participating in Medicaid, meaning its economics are embedded in channel strategy. This influences decisions around the following:

• Limited distribution networks
• Specialty pharmacy contracting
• Gross-to-net forecasting
• Channel management strategies

Within the context of “The Great Repricing,” the 340B program acts as a net price accelerant, compressing manufacturer economics faster than commercial market dynamics alone.

Combined with the MFP provisions of the IRA, this dynamic creates a compelling baseline case for list price reductions. Evidence of this emerged in 2026 when six of the first 10 MFP-selected products reduced their WAC by roughly half.

The Emergence of Global Price Benchmarking

Since this article series began in November 2025, additional policy developments suggest that the government’s role as price setter is expanding even further.

In late 2025 and early 2026, federal policymakers introduced three demonstration models—GLOBE, GUARD and GENEROUS—that, collectively, apply forms of most-favored-nation pricing across major government programs.

These models link U.S. drug prices to international benchmarks, effectively importing global price references into the domestic reimbursement system.

• GLOBE applies international benchmark pricing to selected Medicare Part B drugs.
• GUARD introduces similar benchmarking within Medicare Part D.
• GENEROUS proposes a voluntary Medicaid model in which manufacturers provide enhanced rebates tied to international pricing in exchange for standardized coverage across participating states.

Taken together, these initiatives represent a significant policy evolution. Government is no longer simply negotiating prices; it is anchoring them to global comparators.

For decades, manufacturers managed international markets independently—accepting lower prices abroad while preserving higher net prices in the United States. International reference pricing begins to collapse that separation.

As these models evolve, manufacturers will increasingly need to consider global pricing coherence, not just domestic payer segmentation.

Compliance Now Shapes Pricing Strategy

One of the most underappreciated consequences of the government payer economy is how deeply compliance considerations now shape commercial decision-making.

Best price calculations, bundled discount rules, bona fide service fee scrutiny and channel separation requirements are no longer peripheral legal concerns. They are structural constraints that influence how manufacturers design pricing strategies.

In a market where a single pricing decision can cascade through Medicaid, 340B, Medicare and FSS exposure, manufacturers must begin with governmental compliance logic rather than attempting to retrofit compliance after the fact.

This represents a fundamental reversal of the traditional pricing playbook, and manufacturers that cling to a high WAC/high rebate strategy, especially post loss of exclusivity, aren’t thinking through the mechanics with an optimized net revenue mindset. Having worked with several companies and teams on this, the teams in charge of these decisions work in silos, and those that should see the big picture—finance and brand marketing—aren’t typically getting the advice they need to see how it’s all connected.

Looking Ahead

In the next installment of “The Great Repricing,” we will explore the continued rise of the self-pay economy and how new telehealth, digital pharmacies, transparent pricing models and direct-to-patient programs are reshaping the way patients access medications and how the old guard of classic brick-and-mortar retail need to take what they’ve been doing for generics and embrace a world returning to brands. With most major blockbusters going off patent by the end of the decade, we’re likely to see a huge reduction in the role that brands play, maybe not so much in specialty product categories, but definitely in general medicine. Launching a new brand in a drug class with generics is a tough game these days.

As government increasingly sets price ceilings and commercial economics continue to evolve, the cash market may ultimately prove to be the most dynamic, and disruptive, payer economy of all.

The central theme of “The Great Repricing” series is that the U.S. pharmaceutical market is no longer governed by a single pricing system. Instead, three payer economies — commercial, government and self-pay — are emerging with different incentives, regulatory structures and access pathways. The manufacturers that succeed in the coming decade will be those that learn to navigate all three simultaneously.